The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...
The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...
The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult pat ...
Researchers found that radiotherapy may reduce immune cells in the tumor-immune microenvironment, potentially impacting ...
A far shorter, simpler, and less toxic treatment protocol for patients with triple-negative breast cancer produced outcomes ...
The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...
Triple negative breast cancer wreaks a particularly heavy toll in certain regions and populations, with stark differences in both incidence and survival rates ...
GlobalData on MSN8d
Genentech’s Itovebi combo hits overall survival endpoint in HER2- breast cancerThe Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance ...
This study presents fundamental insights into overcoming resistance in hormone receptor-positive breast cancer by demonstrating that sustained CDK4/6 inhibitor treatment, either alone or in ...
Two dots per cells would signal the presence of the 2 normal HER-2/neu gene copies, and serve as internal control. A clear positive appears as a large gene copy cluster or > 10 signals/nucleus.
Key players include the HER2 (human epidermal growth factor receptor 2) and BRCA (breast cancer gene) mutations ... associated molecules as therapeutic targets and early diagnostic markers. In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback